230 related articles for article (PubMed ID: 28235630)
1. Comprehensive immunohistochemical analysis of histone deacetylases in pancreatic neuroendocrine tumors: HDAC5 as a predictor of poor clinical outcome.
Klieser E; Urbas R; Stättner S; Primavesi F; Jäger T; Dinnewitzer A; Mayr C; Kiesslich T; Holzmann K; Di Fazio P; Neureiter D; Swierczynski S
Hum Pathol; 2017 Jul; 65():41-52. PubMed ID: 28235630
[TBL] [Abstract][Full Text] [Related]
2. HDAC-Linked "Proliferative" miRNA Expression Pattern in Pancreatic Neuroendocrine Tumors.
Klieser E; Urbas R; Swierczynski S; Stättner S; Primavesi F; Jäger T; Mayr C; Kiesslich T; Fazio PD; Helm K; Neureiter D
Int J Mol Sci; 2018 Sep; 19(9):. PubMed ID: 30223590
[TBL] [Abstract][Full Text] [Related]
3. Endoplasmic Reticulum Stress in Pancreatic Neuroendocrine Tumors is Linked to Clinicopathological Parameters and Possible Epigenetic Regulations.
Klieser E; Illig R; Státtner S; Primavesi F; Jáger T; Swierczynski S; Kiesslich T; Kemmerling R; Bollmann C; Di Fazio P; Neureiter D
Anticancer Res; 2015 Nov; 35(11):6127-36. PubMed ID: 26504039
[TBL] [Abstract][Full Text] [Related]
4. Mitotic count by phosphohistone H3 immunohistochemical staining predicts survival and improves interobserver reproducibility in well-differentiated neuroendocrine tumors of the pancreas.
Voss SM; Riley MP; Lokhandwala PM; Wang M; Yang Z
Am J Surg Pathol; 2015 Jan; 39(1):13-24. PubMed ID: 25353284
[TBL] [Abstract][Full Text] [Related]
5. Improving fine needle aspiration to predict the tumor biological aggressiveness in pancreatic neuroendocrine tumors using Ki-67 proliferation index, phosphorylated histone H3 (PHH3), and BCL-2.
Zhao CL; Dabiri B; Hanna I; Lee L; Xiaofei Z; Hossein-Zadeh Z; Cao W; Allendorf J; Rodriguez AP; Weng K; Turunbedu S; Boyd A; Gupta M
Ann Diagn Pathol; 2023 Aug; 65():152149. PubMed ID: 37119647
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells.
Wanek J; Gaisberger M; Beyreis M; Mayr C; Helm K; Primavesi F; Jäger T; Di Fazio P; Jakab M; Wagner A; Neureiter D; Kiesslich T
Int J Mol Sci; 2018 Oct; 19(10):. PubMed ID: 30321986
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylated Histone H3 (PHH3) Is a Superior Proliferation Marker for Prognosis of Pancreatic Neuroendocrine Tumors.
Villani V; Mahadevan KK; Ligorio M; Fernández-Del Castillo C; Ting DT; Sabbatino F; Zhang I; Vangel M; Ferrone S; Warshaw AL; Lillemoe KD; Wargo J; Deshpande V; Ferrone CR
Ann Surg Oncol; 2016 Dec; 23(Suppl 5):609-617. PubMed ID: 27020585
[TBL] [Abstract][Full Text] [Related]
8. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer.
Aghdassi A; Sendler M; Guenther A; Mayerle J; Behn CO; Heidecke CD; Friess H; Büchler M; Evert M; Lerch MM; Weiss FU
Gut; 2012 Mar; 61(3):439-48. PubMed ID: 22147512
[TBL] [Abstract][Full Text] [Related]
9. Significance of DNA methyltransferase-1 and histone deacetylase-1 in pancreatic cancer.
Wang W; Gao J; Man XH; Li ZS; Gong YF
Oncol Rep; 2009 Jun; 21(6):1439-47. PubMed ID: 19424621
[TBL] [Abstract][Full Text] [Related]
10. Short article: Evaluation of O6-methylguanine-DNA methyltransferase as a predicting factor of response to temozolomide-based chemotherapy in well-differentiated metastatic pancreatic neuroendocrine tumors.
Girot P; Dumars C; Mosnier JF; Muzellec L; Senellart H; Foubert F; Caroli-Bosc FX; Cauchin E; Regenet N; Matysiak-Budnik T; Touchefeu Y
Eur J Gastroenterol Hepatol; 2017 Jul; 29(7):826-830. PubMed ID: 28328619
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase (HDAC)-1, -2, -4 and -6 expression in human pancreatic adenocarcinoma: associations with clinicopathological parameters, tumor proliferative capacity and patients' survival.
Giaginis C; Damaskos C; Koutsounas I; Zizi-Serbetzoglou A; Tsoukalas N; Patsouris E; Kouraklis G; Theocharis S
BMC Gastroenterol; 2015 Oct; 15():148. PubMed ID: 26502922
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase-1 and -2 expression in mobile tongue squamous cell carcinoma: associations with clinicopathological parameters and patients survival.
Theocharis S; Klijanienko J; Giaginis C; Rodriguez J; Jouffroy T; Girod A; Alexandrou P; Sastre-Garau X
J Oral Pathol Med; 2011 Oct; 40(9):706-14. PubMed ID: 21457345
[TBL] [Abstract][Full Text] [Related]
13. Expression of histone deacetylases 1, 2 and 3 in histological subtypes of testicular germ cell tumours.
Fritzsche FR; Hasler A; Bode PK; Adams H; Seifert HH; Sulser T; Moch H; Barghorn A; Kristiansen G
Histol Histopathol; 2011 Dec; 26(12):1555-61. PubMed ID: 21972094
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of endoscopic ultrasonography-guided fine needle aspiration for pancreatic neuroendocrine tumor grading.
Sugimoto M; Takagi T; Hikichi T; Suzuki R; Watanabe K; Nakamura J; Kikuchi H; Konno N; Waragai Y; Asama H; Takasumi M; Watanabe H; Obara K; Ohira H
World J Gastroenterol; 2015 Jul; 21(26):8118-24. PubMed ID: 26185384
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC.
Quint K; Agaimy A; Di Fazio P; Montalbano R; Steindorf C; Jung R; Hellerbrand C; Hartmann A; Sitter H; Neureiter D; Ocker M
Virchows Arch; 2011 Aug; 459(2):129-39. PubMed ID: 21713366
[TBL] [Abstract][Full Text] [Related]
16. CD133 expression in well-differentiated pancreatic neuroendocrine tumors: a potential predictor of progressive clinical courses.
Sakai Y; Hong SM; An S; Kim JY; Corbeil D; Karbanová J; Otani K; Fujikura K; Song KB; Kim SC; Akita M; Nanno Y; Toyama H; Fukumoto T; Ku Y; Hirose T; Itoh T; Zen Y
Hum Pathol; 2017 Mar; 61():148-157. PubMed ID: 27864124
[TBL] [Abstract][Full Text] [Related]
17. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
Hayashi A; Horiuchi A; Kikuchi N; Hayashi T; Fuseya C; Suzuki A; Konishi I; Shiozawa T
Int J Cancer; 2010 Sep; 127(6):1332-46. PubMed ID: 20049841
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Ki-67 index in EUS-FNA specimens for the assessment of malignancy risk in pancreatic neuroendocrine tumors.
Hasegawa T; Yamao K; Hijioka S; Bhatia V; Mizuno N; Hara K; Imaoka H; Niwa Y; Tajika M; Kondo S; Tanaka T; Shimizu Y; Kinoshita T; Kohsaki T; Nishimori I; Iwasaki S; Saibara T; Hosoda W; Yatabe Y
Endoscopy; 2014 Jan; 46(1):32-8. PubMed ID: 24218309
[TBL] [Abstract][Full Text] [Related]
19. Hormone profiling, WHO 2010 grading, and AJCC/UICC staging in pancreatic neuroendocrine tumor behavior.
Morin E; Cheng S; Mete O; Serra S; Araujo PB; Temple S; Cleary S; Gallinger S; Greig PD; McGilvray I; Wei A; Asa SL; Ezzat S
Cancer Med; 2013 Oct; 2(5):701-11. PubMed ID: 24403235
[TBL] [Abstract][Full Text] [Related]
20. The Impact of Phosphohistone-H3-Assisted Mitotic Count and Ki67 Score in the Determination of Tumor Grade and Prediction of Distant Metastasis in Well-Differentiated Pancreatic Neuroendocrine Tumors.
Ozturk Sari S; Taskin OC; Gundogdu G; Yegen G; Onder S; Keskin M; Saglam S; Ozluk Y; Gulluoglu M; Mete O
Endocr Pathol; 2016 Jun; 27(2):162-70. PubMed ID: 26936845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
